Solid Biosciences (SLDB) Other Accumulated Expenses (2017 - 2024)
Quarterly results put Other Accumulated Expenses at $92000.0 for Q1 2024, up 67.27% from a year ago — trailing twelve months through Mar 2024 was $92000.0 (up 67.27% YoY), and the annual figure for FY2023 was $24000.0, up 71.43%.
Solid Biosciences has reported Other Accumulated Expenses over the past 7 years, most recently at $92000.0 for Q1 2024.
- Other Accumulated Expenses reached $92000.0 in Q1 2024 per SLDB's latest filing, up from $24000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $162000.0 in Q3 2023 and bottomed at $14000.0 in Q4 2022.
- Median Other Accumulated Expenses over the past 4 years was $67000.0 (2021), compared with a mean of $74250.0.
- Peak annual rise in Other Accumulated Expenses hit 408.7% in 2023, while the deepest fall reached 63.33% in 2023.
- Over 4 years, Other Accumulated Expenses stood at $35000.0 in 2021, then crashed by 60.0% to $14000.0 in 2022, then skyrocketed by 71.43% to $24000.0 in 2023, then skyrocketed by 283.33% to $92000.0 in 2024.
- Business Quant data shows Other Accumulated Expenses for SLDB at $92000.0 in Q1 2024, $24000.0 in Q4 2023, and $162000.0 in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 92,000.00 |
| Dec 31, 2023 | 24,000.00 |
| Sep 30, 2023 | 162,000.00 |
| Jun 30, 2023 | 117,000.00 |
| Mar 31, 2023 | 55,000.00 |
| Dec 31, 2022 | 14,000.00 |
| Sep 30, 2022 | 85,000.00 |
| Jun 30, 2022 | 23,000.00 |
| Mar 31, 2022 | 150,000.00 |
| Dec 31, 2021 | 35,000.00 |
| Sep 30, 2021 | 73,000.00 |
| Jun 30, 2021 | 61,000.00 |
| Dec 31, 2019 | 52,000.00 |
| Sep 30, 2019 | 221,000.00 |
| Jun 30, 2019 | 278,000.00 |
| Mar 31, 2019 | 355,000.00 |
| Dec 31, 2018 | 382,000.00 |
| Dec 31, 2017 | 233,000.00 |